Related Experiment Video
Updated: Dec 29, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Development of hypocomplementemic urticarial vasculitis during certolizumab pegol treatment for rheumatoid arthritis:
Yoshiro Horai1,2, Hiroshi Ishikawa3, Nozomi Iwanaga1
1Department of Rheumatology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
What Is Known And Objective:
Tumour necrosis factor-α-blocking agents potentially cause vasculitis. However, no study has reported on the association between hypocomplementemic urticarial vasculitis (HUV) and certolizumab pegol (CZP) usage.
Case Description:
We present the first case of HUV development during CZP treatment for rheumatoid arthritis. Hypocomplementemic urticarial vasculitis improved after CZP was discontinued and the dose of oral prednisolone was increased.
What Is New And Conclusion:
Clinicians should be aware about the potential development of HUV during CZP treatment, which is presumed to be safe considering its unique structural characteristics that differ from those of other tumour necrosis factor-α-blocking agents.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Pericarditis I: Introduction
Pericarditis III: Medical Management

